Allermi, a San Francisco-based wellness and fitness services company, has secured $3.5 million in seed funding led by FourSight Capital Partners.

Founded by Shani Bocian, Allermi is changing the way people treat their allergies with evidence-based medicine. Using custom combinations of clinically-proven ingredients, Allermi offers an innovative solution to address all symptoms in one simple spray. 

The funding will be used to expand Allermi’s clinical trials and research efforts to create personalized treatments for different types of allergies. It will also help the company grow its team and build out its technology platform for data collection and analysis around allergy treatment outcomes.

“We are thrilled to partner with FourSight Capital Partners as we continue our mission of helping people find relief from their allergies using evidence-based treatments,” said Shani Bocian, Co-Founder of Allermi. “This investment will allow us to further refine our allergy treatment protocols so that they can be tailored to each individual's needs, ultimately providing more effective solutions than those currently available on the market today."